Implications of the Incidental Finding of a MYCN Amplified Adrenal Tumor: A Case Report and Update of a Pediatric Disease Diagnosed in Adults

Author:

Koumarianou Anna1ORCID,Oikonomopoulou Panagiota2,Baka Margarita3,Vlachodimitropoulos Dimitrios4,Argentos Stylianos5,Piperos Theodoros6ORCID,Christodoulou Maria-Ioanna7ORCID,Theodoulou Kakoulis6,Mariolis-Sapsakos Theodoros6

Affiliation:

1. Fourth Department of Internal Medicine, Attikon University Hospital, Rimini 1, 12462 Haidari, Athens, Greece

2. Department of Medical Oncology, St Bartholomew’s Hospital, West Smithfield, London EC1A 7BE, UK

3. Department of Pediatric Hematology-Oncology, “Pan. & Aglaia Kyriakou” Children's Hospital, Thivon & Livadias Street, 11527 Athens, Greece

4. Laboratory Forensic Medicine and Toxicology, Evgenidion Hospital University of Athens, 76th V. Sofias, 11528 Athens, Greece

5. Radiology Department, Attikon University Hospital, 1st Rimini Street, 12462 Athens, Greece

6. Department of Surgery, Evgenidion Hospital, 20th Papadiamantopoulou Street, 11528 Athens, Greece

7. Department of Biochemistry and Molecular Biology, University of Athens, Panepistimiopolis, 15701 Athens, Greece

Abstract

MYCN is a well-known oncogene overexpressed in different human malignancies including neuroblastoma, rhabdomyosarcoma, medulloblastoma, astrocytoma, Wilms’ tumor, and small cell lung cancer. While neuroblastoma is one of the most common childhood malignancies, in adults it is extremely rare and its treatment is based on pediatric protocols that take into consideration stage and genotypic features, such as MYCN amplification. Although neuroblastoma therapy has evolved, identification of early stage patients who need chemotherapy continues to pose a therapeutic challenge. The emerging prognostic role of MYCN phenotype of this disease is currently under investigation as it may redefine MYCN amplified subgroups. We describe an unusual case of adult neuroblastoma with MYCN amplification diagnosed incidentally and discuss possible therapeutic dilemmas.

Publisher

Hindawi Limited

Subject

Oncology

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3